Combination oral agent and insulin therapy for type 2 diabetes mellitus.
Curr Diab Rep
; 1(2): 106-11, 2001 Oct.
Article
en En
| MEDLINE
| ID: mdl-12643105
Type 2 diabetes is a chronic metabolic disorder that results from defects in both insulin secretion and insulin action. Over time, there is progressive beta-cell failure. Combination oral and insulin therapy aims at treating both the defects in underlying pathophysiology and replacing insulin once beta-cell failure has occurred. Combination therapy is routinely used in the management of diabetes to reduce hemoglobin A1c, weight gain, and the number of insulin injections a patient requires. This article examines the effects of combining various oral agents with insulin on glycemic control, hypoglycemia, weight gain, and nonglycemic benefits of these combinations.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Compuestos de Sulfonilurea
/
Tiazoles
/
Tiazolidinedionas
/
Diabetes Mellitus Tipo 2
/
Hipoglucemiantes
/
Insulina
Límite:
Humans
Idioma:
En
Revista:
Curr Diab Rep
Asunto de la revista:
ENDOCRINOLOGIA
Año:
2001
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos